- Previous Close
108.20 - Open
107.00 - Bid 101.20 x --
- Ask 106.30 x --
- Day's Range
102.90 - 107.00 - 52 Week Range
100.50 - 126.30 - Volume
30,531 - Avg. Volume
56,923 - Market Cap (intraday)
9.2B - Beta (5Y Monthly) 0.64
- PE Ratio (TTM)
21.26 - EPS (TTM)
4.88 - Earnings Date Feb 13, 2025
- Forward Dividend & Yield 1.20 (1.06%)
- Ex-Dividend Date Jun 2, 2023
- 1y Target Est
--
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Dysport for motor muscular disorders and medical aesthetics; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; and Tazverik to treat third-line follicular lymphoma. The company also provides NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome or chronic renal insufficiency, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. In addition, it offers Xermelo for the treatment of carcinoid syndrome; and Cometriq to treat medullary thyroid cancer. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.
www.ipsen.com5,300
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 0MH6.IL
View MorePerformance Overview: 0MH6.IL
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is CAC 40 (^FCHI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 0MH6.IL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 0MH6.IL
View MoreValuation Measures
Market Cap
8.51B
Enterprise Value
8.26B
Trailing P/E
24.30
Forward P/E
10.26
PEG Ratio (5yr expected)
0.73
Price/Sales (ttm)
2.42
Price/Book (mrq)
2.05
Enterprise Value/Revenue
2.31
Enterprise Value/EBITDA
7.11
Financial Highlights
Profitability and Income Statement
Profit Margin
13.70%
Return on Assets (ttm)
9.39%
Return on Equity (ttm)
12.52%
Revenue (ttm)
3.28B
Net Income Avi to Common (ttm)
406.2M
Diluted EPS (ttm)
4.88
Balance Sheet and Cash Flow
Total Cash (mrq)
413.4M
Total Debt/Equity (mrq)
20.03%
Levered Free Cash Flow (ttm)
1.16B